Short answer
Organogenesis Holdings Inc. (ORGO) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $44M (down 56.7% year over year) with net income of −$96M.
Q2 2026 key financials · XBRL
- Revenue
- $44M
- −56.7% YoY · +17.5% QoQ
- Net income
- −$96M
- −925.0% YoY · −81.1% QoQ
- Operating margin
- -116.5%
- EPS (diluted)
- −$0.77
- −670.0% YoY · −75.0% QoQ
Source: XBRL data from the Organogenesis Holdings Inc. (ORGO) Q2 2026 10-Q on SEC EDGAR. USD.
Organogenesis Holdings Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Total revenue $43.755M, down 57% YoY from $101.005M
- Gross margin 43.7% vs 72.4% YoY; operating loss $50.992M vs $12.576M
- Advanced Wound Care revenue $36.146M, down 61%; Surgical & Sports Medicine $6.659M, down 18%
- Six-month operating cash use $10.526M vs $52.808M; cash and equivalents $46.1M at June 30
- CMS reimbursement changes and market disruption drove declines; Dermagraft relaunch timing no longer projected
Risk Factors
- No newly added, updated, regulatory, operational, competitive, market, or financial risks identifiable from supplied text
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Organogenesis Holdings Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.